Teva Pharmaceuticals Recalls 21,930 Octreotide Acetate Cartons Over Sterility Concerns from Greek Manufacturer
Teva Pharmaceuticals USA, Inc. has initiated a nationwide Class II recall of 21,930 cartons of Octreotide Acetate for Injectable Suspension. This critical action stems from a lack of sterility assurance identified during an FDA inspection at its contract manufacturer, Pharmathen International S.A. in Greece, highlighting significant quality system deficiencies impacting patient safety and supply chain integrity.
FDA-Mandated Recall: Teva's Octreotide Acetate Impacted by Sterility Assurance Failures at Greek Facility
Teva Pharmaceuticals USA, Inc. has initiated a Class II recall, D-0406-2026, for 21,930 cartons of Octreotide Acetate for Injectable Suspension. This critical action, voluntarily undertaken by Teva but prompted by regulatory findings, addresses a fundamental lack of assurance of sterility. The root cause has been traced to significant quality system deficiencies identified by the U.S. Food and Drug Administration (FDA) during a routine inspection at the contract manufacturer, Pharmathen International S.A., located in Rodopi, Greece. This recall affects multiple lots, including Lot: 4400401 (Exp.: 6/30/2026); 4401393, 4401494, 4401604 (Exp.: 9/31/2026); and 4500564, 4500601, 4500707, 4500796, 4500859, 4500918, 4500919, 4501006 (Exp.: 3/31/2027). For procurement directors and supply chain VPs, this means an immediate disruption to the supply of a product used for gluteal intramuscular injection, necessitating rapid assessment of current stock and alternative sourcing strategies to maintain patient access and avoid treatment interruptions.
Supply Chain Vulnerability: Nationwide Distribution of Octreotide Acetate at Risk
The recall of Teva's Octreotide Acetate for Injectable Suspension, distributed nationwide across the USA, exposes significant vulnerabilities within the pharmaceutical supply chain. With 21,930 cartons of the 30 mg single-dose 8 mL vial kits (NDC 0480-9262-08) impacted, companies relying on this specific product face immediate challenges in maintaining continuity of care. Octreotide Acetate is a critical human prescription drug used for various conditions, and its unavailability can have direct clinical consequences. Procurement teams must immediately quantify their exposure to these specific recalled lots and assess the broader impact on their inventory and distribution networks. The recall's 'Ongoing' status indicates that the full scope of the issue and remediation efforts are still unfolding, demanding continuous monitoring. Business development executives should evaluate potential market gaps created by this disruption and explore opportunities for alternative products or formulations, while regulatory affairs heads must prepare for increased scrutiny on their own supply chains for similar sterility assurance risks, particularly concerning contract manufacturers.
Contract Manufacturing Oversight: Lessons from Pharmathen International S.A.'s Deficiencies
The identified quality system deficiencies at Pharmathen International S.A. in Greece, the contract manufacturer for Teva's Octreotide Acetate, underscore the critical importance of robust oversight in outsourced manufacturing. For regulatory affairs and quality assurance leaders, this event highlights that ultimate responsibility for product quality and patient safety remains with the marketing authorization holder, Teva Pharmaceuticals USA, Inc., regardless of manufacturing location. The FDA's findings at Pharmathen International S.A. serve as a stark reminder that geographical distance does not diminish regulatory expectations for Good Manufacturing Practices (GMP). This incident is not isolated; recent parallel events, such as the FDA Class II recalls for Essential Wellness Pharma's Progesterone Injection and Spectra Medical Devices' Lidocaine HCl Injection, both due to sterility assurance failures, indicate a systemic industry challenge. Companies must re-evaluate their contract manufacturing organization (CMO) qualification processes, audit frequencies, and ongoing performance monitoring to prevent similar sterility breaches that can lead to costly and reputation-damaging recalls. Proactive risk assessments of CMOs, especially those producing sterile injectables, are paramount to mitigate future supply chain disruptions.
Strategic Sourcing Imperatives: Identifying Alternative Sterile Injectable Suppliers
In light of the Teva Octreotide Acetate recall, procurement directors must immediately activate contingency plans for sourcing sterile injectables. The absence of readily available alternative suppliers in the public domain for this specific product, as indicated by our intelligence, means that identifying and qualifying new sources for Octreotide Acetate will be a time-sensitive and complex undertaking. Supply chain VPs should prioritize mapping all critical sterile injectable products and their respective manufacturing sites, assessing the regulatory compliance history of each supplier. Diversifying the supplier base, both geographically and by manufacturer, is no longer a best practice but a commercial imperative to build resilience against such unforeseen quality events. Qualification timelines for new sterile injectable suppliers can range from 12 to 24 months, depending on regulatory requirements and internal validation processes. Companies that have not already initiated multi-sourcing strategies for their critical drug products will face significant pressure to secure supply, potentially leading to increased costs and extended lead times. This situation demands a proactive approach to supplier relationship management and risk mitigation.
Navigating Regulatory Scrutiny: Teva's Path Forward and Industry-Wide Compliance Lessons
The 'Ongoing' status of this Class II recall signifies that Teva Pharmaceuticals USA, Inc. is actively engaged in addressing the FDA's findings and managing the market impact. For regulatory affairs heads, this means Teva will be expected to submit comprehensive corrective and preventive action (CAPA) plans to the FDA, detailing how the quality system deficiencies at Pharmathen International S.A. will be remediated. The FDA will closely monitor these actions, and a re-inspection of the Greek facility is highly probable. Failure to adequately address the identified issues could escalate to further regulatory actions, including an FDA Warning Letter to Pharmathen International S.A. or even an Import Alert, which would severely restrict future shipments of products manufactured at that facility into the U.S. Business development executives should anticipate potential delays in new product approvals or market entries if their manufacturing partners exhibit similar compliance issues. This event serves as a critical reminder for the entire industry to continuously invest in robust quality management systems and to ensure that all contract manufacturing partners adhere to the highest global GMP standards to prevent similar disruptions and maintain public trust.